Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00967473
Other study ID # C-08-062
Secondary ID
Status Completed
Phase N/A
First received August 25, 2009
Last updated June 23, 2011
Start date August 2009
Est. completion date May 2010

Study information

Verified date June 2011
Source Alcon Research
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to describe rates of spatial distortions related to intraocular lens (IOL) misalignment for ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 when implanted bilaterally into the capsular bag following phacoemulsification in adult patients with bilateral cataract and regular corneal astigmatism. Subjects were implanted with the Model SN60T9 in the first operative (study) eye and either Model SN60T9 or Model SN60T8 in the second operative eye.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Adults, 21 years of age or older at the time of surgery, of either gender or any race, diagnosed with bilateral cataracts;

- Calculated lens power is within the available range;

- Willing and able to complete all required postoperative visits;

- Planned cataract removal by phacoemulsification;

- Potential postoperative visual acuity of 0.2 logMAR or better in study eyes;

- Preoperative astigmatism of 4.11 - 4.62 Diopter (D) of predicted crossed cylinder as calculated by the study specific web-based AlconĀ® Toric IOL Calculator in the first operative eye. Corneal incisions made to reduce astigmatism will not be allowed during the course of the study;

- Preoperative astigmatism of 3.60 - 4.62 D of predicted crossed cylinder as calculated by study specific web-based AlconĀ® Toric IOL Calculator in the second operative eye;

- Clear intraocular media other than cataract;

- Able to comprehend and sign a statement of informed consent;

- Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR;

- Pupil size greater than or equal to 6 mm after dilation;

- The subject must be able to undergo second eye surgery within 30 days of first eye surgery.

Exclusion Criteria:

- Irregular corneal astigmatism;

- Keratopathy/Keratectasia - any corneal abnormality, other than regular corneal astigmatism, including but not limited to the following; keratoconus, keratoglobus, keratolysis, keratomalacia, keratomycosis, and corneal plana;

- Any inflammation or edema (swelling) of the cornea, including but not limited to the following; keratitis, keratoconjunctivitis, and keratouveitis;

- Previous corneal refractive surgery;

- Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.2 logMAR;

- Amblyopia;

- Clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy);

- Diabetic retinopathy;

- Extremely shallow anterior chamber, not due to swollen cataract;

- Microphthalmos;

- Previous retinal detachment;

- Previous corneal transplant;

- Recurrent severe anterior or posterior segment inflammation of unknown etiology;

- Rubella or traumatic cataract;

- Iris neovascularization;

- Uncontrolled glaucoma;

- Aniridia;

- Optic nerve atrophy;

- Pregnancy;

- Any subject currently participating in another investigational drug or device study that may confound the results of this investigation.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Adult Patients With Bilateral Cataracts.
  • Cataract

Intervention

Device:
ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.
ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.

Locations

Country Name City State
United States Alcon Call Center for Trial Locations Fort Worth Texas

Sponsors (1)

Lead Sponsor Collaborator
Alcon Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting Spatial Distortions Related to Intraocular Lens (IOL) Misalignment Rates of spatial distortions were evaluated by use of the Visual Distortion Questionnaire (VDQ). The VDQ evaluates the rate & frequency of subjects' experiences with potential visual distortions. The fewer the patients that report visual distortions, the better. The VDQ is a binocular assessment, therfore the subject will use both eyes to evaluate visual distortions. Before Surgery and 180 days after second eye implant Yes
Primary Reduction of Cylinder Percentage of subjects with reduction in post-operative refractive cylinder (amount of astigmatism) compared to pre-operative keratometric cylinder in the study eye. The post-operative refractive cylinder should be significantly lower than it was pre-operatively. 6 months after surgery on second eye No
Primary Lens Axis Misalignment Comparison of where the surgeon intended to place the lens axis versus final placement of the lens during the surgical procedure, measured in degrees. This number should be close to zero as there should be minimal difference between the two numbers. This assessment is only for the study eye. Time of surgery No